C4 Therapeutics presents cemsidomide biomarker data at IMS Annual Meeting
New data from Phase 1 and Phase 1b trials show T-cell activation effects, and a safety committee cleared the first Phase 1b dose level for expansion.
SEC filing
Latest
2 stories
Friday, September 25
Tuesday, August 11
C4 Therapeutics reports Q2 2026 results, cemsidomide trials on track for 2027 data
The company said its Phase 2 MOMENTUM trial and a Phase 1b combination study of cemsidomide remain on track, with cash extending runway to the end of 2028.
SEC filing